RGPX

Regenerex Pharma, Inc. is engaged in the development and commercialization of advanced wound care healing products. The Company operates through three distinct proprietary technologies designed to address different wound care needs: Chronic Wound Closure Technology, Acute Wound Acceleration Technology and Contamination Control Technology. Chronic Wound Closure Technology is specifically designed for closing chronic wounds. Acute Wound Acceleration Technology is focused on accelerating closure of acute or surgical wounds. Contamination Control Technology addresses contamination issues across all wound types, including biofilm destruction. Its comprehensive Wound Closure System and protocols effectively treat a broad spectrum of wounds, including diabetic ulcers, pressure ulcers, venous ulcers, burns, and surgical wounds. Its proprietary active ingredient, QBx, addresses a critical issue in wound healing by down-regulating the production of specific proteases and matrix metalloproteases.